Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × fludarabine × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1 Completed

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT02588612 2021-09-05

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

10 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Clinical Trials

ACTolog

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer